Clinical Research Directory
Browse clinical research sites, groups, and studies.
Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Sponsor: Taichung Veterans General Hospital
Summary
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide and a significant public health issue. MASLD may progress to liver cirrhosis and/or hepatocellular carcinoma. Although previous evidence suggests that aspirin has antisteatotic and antifibrotic effects on the liver, a randomized controlled trial assessing long-term efficacy and safety of aspirin in MASLD patients has yet to be conducted. This study aims to conduct a randomized controlled trial to evaluate the efficacy of aspirin in treating MASLD.
Official title: Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2025-05-05
Completion Date
2032-12-31
Last Updated
2025-05-11
Healthy Volunteers
No
Interventions
Aspirin 81 mg Enteric Coated Tab - 1 tablet
Participants will be randomly assigned in a 1:1 ratio to receive daily low-dose (81mg) aspirin or a placebo
Placebo
Participants will be randomly assigned in a 1:1 ratio to receive daily low-dose (81mg) aspirin or a placebo
Locations (1)
Taichung Veterans General Hospital
Taichung, Taiwan, Taiwan